Your browser doesn't support javascript.
loading
Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy.
Zhao, Ting; Liang, Ce; Zhao, Yanrong; Xue, Xiangdong; Ma, Zhao; Qi, Jinlong; Shen, Haitao; Yang, Shaokun; Zhang, Jia; Jia, Qingzhong; Du, Qing; Cao, Deying; Xiang, Bai; Zhang, Hailin; Qi, Xianrong.
Affiliation
  • Zhao T; Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Liang C; Department of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Zhao Y; Department of Hematology, Hebei Children's Hospital, Hebei Medical University, Shijiazhuang, 050031, Hebei, China.
  • Xue X; School of Pharmaceutical Science, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Ma Z; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.
  • Qi J; Department of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Shen H; Laboratory of Pathology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Yang S; Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Zhang J; Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Jia Q; Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Du Q; Department of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Cao D; Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
  • Xiang B; Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. deyingcao@hebmu.edu.cn.
  • Zhang H; Key Laboratory of Hebei Province for Innovative Drug Research and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. baixiang@hebmu.edu.cn.
  • Qi X; Department of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. zhanghl@hebmu.edu.cn.
J Nanobiotechnology ; 20(1): 177, 2022 Apr 02.
Article in En | MEDLINE | ID: mdl-35366888
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms / Antineoplastic Agents Language: En Journal: J Nanobiotechnology Year: 2022 Document type: Article Affiliation country: China Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms / Antineoplastic Agents Language: En Journal: J Nanobiotechnology Year: 2022 Document type: Article Affiliation country: China Country of publication: United kingdom